Elastin is degraded during vascular ageing and its products, elastin-derived peptides (EP), are present in the human blood circulation. EP binds to the elastin receptor complex (ERC) at the cell surface, composed of elastin-binding protein (EBP), a cathepsin A and a neuraminidase 1. Some in vitro functions have clearly been attributed to this binding, but the in vivo implications for arterial diseases have never been clearly investigated.
Introduction
Atherosclerosis is a complex, multi-factorial chronic inflammatory disease affecting medium-to large-sized arteries. Recent findings have established a fundamental role for inflammation in mediating the different stages of this disease, revealing an attractive diversity of potential targets that can be exploited in the treatment of this pathology. During early steps of this age-associated inflammatory disease, infiltrated monocytes-macrophages by producing cytokines and reactive oxygen species (ROS) sustain a pro-inflammatory environment in the subendothelial space, resulting in the progression of fatty streak. Owing to this local inflammatory context, the extracellular matrix (ECM) of the arterial wall, mostly composed of the elastin and collagen, is importantly degraded by proteases secreted by infiltrated neutrophil/ macrophage. For a long time, the ECM was described as providing support for cells and facilitating the mechanical properties of tissues, but it is now known to also regulate cell phenotype and fate. In the last few years, particular attention has been given to the role of elastin † Both authors contributed equally to this work. degradation in physiopathological processes as it has been demonstrated that the release of elastases drives the production of elastinderived peptides (EP) (elastokines) that are proposed to be associated with arterial pathologies.
1 EP are present in the blood of the general population where their serum concentration fluctuates from the ng/mL to the mg/mL range depending on both the procedure used for EP dosage and the type of atherosclerotic disease of the patient. 2 -4 Nevertheless, a definitive role for EP in the development of arterial diseases in vivo has not yet been demonstrated. In vitro, EP control a wide range of biological effects that may play beneficial or deleterious roles on atherosclerosis development. For example, EP are reported to induce monocyte migration and ROS production leading to low-density lipoprotein (LDL) oxidation. 5, 6 This suggests that they could aggravate atherosclerosis development in vivo and may play a central role in this pathology. In contrast, EP are also reported to mediate endothelial cell nitric oxide production that contributes towards slowing down atheroma plaque formation. 7 In smooth muscle cells, EP are also able to promote cell proliferation, suggesting a potential impact on plaque stabilization in vivo. 8 EP is thought to elicit most of these effects by activation of the elastin receptor complex (ERC) which is formed by the association with an elastin-binding protein (EBP) (inactive splicing variant of b-galactosidase protein) and two membrane proteins: the cathepsin A (CathA) or protective protein (PP) and the associated neuraminidase (Neu1). Neu1 was identified as the protein responsible for signal transduction from the ERC leading to the activation of various signalling modules that differ depending on the cell type. 1, 9, 10 In fibroblasts, ERC activation leads to recruitment and activation of the phosphoinositide 3-kinase g (PI3Kg), but the mechanism involved remains unknown. 11 Interestingly, this kinase is highly expressed in haematopoietic cells and plays a key role in inflammatory processes of the arterial wall during atherogenesis.
12,13
Here, we have evaluated the role of EP in atherosclerosis progression and the possible involvement of PI3Kg in this process. In this investigation, we used two existing murine models of atherosclerosis to provide direct evidence that EP enhance atheroma plaque size progression and that this effect could be driven by their action on monocytes through the Neu1 -PI3Kg signalling module. We also show that degradation of elastic lamellae in LDLR 2/2 mice put on an atherogenic diet correlates with atherosclerotic plaque formation. At the same time, the absence of the CathA-Neu1 complex in cells of the haematopoietic lineage abolishes atheroma plaque size progression and leucocyte infiltration, suggesting the involvement of endogenous EP. Altogether our data show a novel function of elastokines in the development of atherogenesis and thus provide new potential targets for the treatment of arterial disease.
Methods

Biological materials
The synthetic peptides VGVAPG and VVGPGA were produced by GeneCust (Luxembourg). The neuraminidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA) was purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). The p110g antibody was purchased from Santa-Cruz Biotechnology (distributed by Tebu, Le Perray en Yvelines, France). Monoclonal antibodies directed against Akt and phosphorylated Akt (threonine 308), and horse radish peroxydase (HRP)-conjugated anti-rabbit antibodies were purchased from Cell Signaling Technology (distributed by Ozyme, Saint-Quentin en Yvelines, France). The enhanced chemiluminescence (ECL) system was purchased from Amersham Biosciences, Inc. (Orsay, France).
Mice
PI3K-deficient (PI3Kg 2/2 ) mice were generated from a C57Bl/6J background as previously described. 13 -15 CathA S190A-Neo mice were on a C57Bl/6J background as previously described. 16 As models of in vivo ath- ) . These mouse models were kept under specific pathogen-free conditions. During experiments, mice were anaesthetized using isoflurane (2%) and were euthanized using cervical dislocation. All animal procedures were in accordance with institutional guidelines on Animal Experimentation and with a French Ministry of Agriculture license. Moreover, this investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health or the Directive 2010/63/EU of the European Parliament.
Kappa-elastin preparation
EP were prepared as described previously. 9 Briefly, insoluble elastin was prepared from bovine ligamentum nuchae by hot alkali treatment. Its purity was assessed by comparing its amino acid composition to that predicted by the elastin gene product. Soluble EP were obtained from insoluble elastin by organo-alkaline hydrolysis. This was achieved using 1 M potassium hydroxide in 80% aqueous ethanol. The mixture of EPs obtained is termed kappa-elastin (kE) and exhibits the same biological and physical properties as elastin hydrolysates obtained using elastase taken from leucocytes.
Bone marrow transplantation
Eight-week-old C57Bl/6J LDLR 2/2 mice were subjected to medullary aplasia by 9-Gy total-body irradiation. We re-populated mice with i. BM. Blood and tissues were collected and analysed as described below. The successful engraftment was confirmed by PCR.
Characterization of atherosclerotic lesions
The hearts were prepared as described previously 13 and the atherosclerotic lesions were estimated according to Paigen et al. 17 Briefly, the heart were washed in phosphate-buffered saline (PBS) and incubated in PBS at 48C for 12 h. Each heart was frozen on a cryostat mount with optimum cutting temperature (OCT) compound (Tissue-Tek), and stored at 2808C. One hundred sections of 10 mm thickness were prepared from the top of the left ventricle, where the aortic valves were first visible, up to a position in the aorta where the valve cusps were just disappearing from the field. After drying for 2 h, the sections were stained with Oil Red O and counterstained with Mayer's haematoxylin. After Oil Red O staining, surface lesion areas were measured by computerassisted image quantification using the Leica QWin software (Leica Microsystems, Wetzlar, Germany). Images were captured with a Sony (Tokyo, Japan) 3CCD video camera.
Immunohistochemistry
Frozen sections from the aortic root were fixed in acetone/methanol, air-dried, and incubated with 10% of relevant serum for 30 min. The following specific primary antibodies were used: anti-monocyte/ macrophage (clone MOMA-2, Serotec, Oxford, UK) and antilymphocyte T/CD3 (clone SP7, Zytomed System, Berlin, Germany). Then, sections were incubated with the corresponding secondary biotinylated antibodies (Dako) and visualized with an avidin-biotinhorseradish peroxidase complex (Vectastain ABC kit, Vector Laboratories) and the 3-3 ′ diaminobenzidine (DAB) peroxidase substrate kit (DakoCytomation, Glostrup, Denmark). Countercolouration was performed with Mayer's haematoxylin. Irrelevant IgGs were used as negative controls.
Analysis of plasmatic cholesterol
Cholesterol levels were measured with a commercial kit: CHOD-PAP (Randox Laboratories, Crumlin, County Antrim, Ireland).
Murine monocyte ROS production assay
Blood taken from mice was centrifuged (400 g) in the presence of a mixture of sodium metrizoate . Cells were counted and their purity was assessed following May-Grunwald-Giemsa colouration. For ROS production, nitroblue tetrazolium (NBT) reduction was used. Cells were stimulated by kE (50 mg/mL), VGVAPG (200 mg/mL), or BSA in the presence or absence of DANA (200 mM), in the presence of NBT. Briefly, 10 4 cells were incubated for 2 h at 378C in 50 mL DMEM (containing or not the different agonists/inhibitors) in which 5 mL of NBT (1.36 mg/mL) was added. NBT reduction leads to a loss of positive charges and to a consequent decrease in its solubility. Its absorption spectrum is subsequently modified leading from yellow (oxidized form) to blue (reduced form, formazan). The generated insoluble formazan is directly measured using a spectrophotometer (Tecan Infinite F200 Pro, Lyon, France) by absorbance (560 nm).
Murine monocyte migration assay
Monocyte migration was evaluated using a Boyden chamber containing Dulbecco's solution in the upper compartment and kE (50 mg/mL) or VGVAPG (200 mg/mL) in the presence or in the absence of DANA (200 mM) in the lower compartment. After 4 h incubation, the membrane between the two chambers was stained with crystal violet and cells were counted using a microscope. Ten different fields were counted for each experiment.
Western blot analysis
Proteins from blood monocytes were dissolved in Laemmli buffer, boiled, separated by SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Immunodetection was achieved using primary antibodies against Akt phosphorylated on Threonine 308 (1/1000), or total Akt (1/1000) overnight at 48C. Membranes were then incubated with HRP-conjugated secondary antibody (anti-rabbit, 1/1000) for 1 h at room temperature, then immunoreactive proteins were detected with ECL reagents according to the manufacturer's instructions.
PI3K activity assay
Cells were washed twice in ice-cold PBS containing 50 mM Na 3 VO 4 , then scraped off into PBS and centrifuged (375 g, 10 min, 48C). Pellets were resuspended and incubated for 15 min at 48C in immunoprecipitation lysis buffer [10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Brij 98, 1 mM Na 3 VO 4 , with added protease inhibitor cocktail]. An insoluble material was removed by centrifugation (20 000 g, 20 min, 48C). Protein concentrations were determined using a bicinchonic acid assay protein assay and equal amounts of proteins were incubated with 10 mg anti-p110g antibodies for 1 h at 48C. The antigen -antibody complexes were incubated with protein G-Plus-Sepharose (Santa-Cruz Biotechnology) for 1 h at 48C, collected by centrifugation, washed three times in immunoprecipitation lysis buffer and then twice with lipid kinase buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 200 mM adenosine). To perform the lipid kinase assay, each pellet was resuspended in 70 mL of lipid kinase buffer supplemented with phosphatidylinositol (PI) and phosphatidylserine (10 mg/mL each), 2.5 mM ATP and 10 mCi 
Elastic fibres breakage analysis
Immediately after sacrifice of mice, thoracic aortas were dissected and then directly frozen in liquid nitrogen. Four-micrometre cryo-sections of OCT-embedded samples were rinsed in PBS for 5 min and conserved with FluorSave TM Reagent (Calbiochem). Autofluorescence of elastin (l excitation /l emission : 410/500 nm) was evaluated using a Zeiss microscope (Axio A1).
Statistical analysis
Comparisons between the different groups were performed using an unpaired t-test. Statistical differences considered significant were probability values P ≤ 0.05 (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 compared with the corresponding control of each experiment). Data are shown as means + SEM.
Results
EP accelerate atherosclerosis development in vivo
To evaluate whether circulating EP play a role in atheroma progression, we used two murine models of atherosclerosis, apolipoprotein E-deficient mice (ApoE 2/2 ) and low-density lipoprotein receptordeficient mice (LDLR 2/2 ). We used young ApoE 2/2 and LDLR
2/2
mice in which elastic fibre degradation in their arterial wall is very low in order to avoid endogenous EP participation (see Supplementary material online, Figure 1 A and B) . To evaluate the effect of circulating EP in early atherosclerosis, 11-weeks-old ApoE 2/2 mice were injected with Elastin peptides potentiate atherosclerosis kE once a week during 6 weeks. kE is an organometallic hydrolysate of elastin that presents the same biological effects as a hydrolysate obtained following digestion of leucocyte elastase. We used a dose of 5 mg/kg kE, a level of EP similar to that found in the general 'atherosclerotic' human population. 3 Analysis of lipid deposition in the aortic root sections of control mice showed fatty streak lesions (on average covering an area of 79 000 mm 2 ), which were highly potentiated by EP injection (155 000 mm 2 ) ( Figure 1A and B) . Total plasmatic cholesterol levels
were not modified by EP injection, suggesting that the increase in the lesion size was not accounted for by changes in plasma cholesterol levels ( Figure 1C) . In parallel, LDLR 2/2 mice were fed an atherogenic diet for 8 weeks to encourage the development of larger atherosclerotic lesions (120 000 mm 2 ) ( Figure 1D and E) and presented higher levels of plasmatic cholesterol ( Figure 1F ). Like ApoE 2/2 mice, these mice also showed a potentiation of atherosclerotic lesion size following EP treatment without any modification of plasmatic cholesterol levels, showing that EP accelerates the development of atherosclerosis in both models. Therefore, these results clearly demonstrate that EP accelerates the initiation of atherosclerosis in vivo.
VGVAPG peptide accelerates atherosclerosis development in vivo
It has been established that diverse elastokines containing the XGXXPG repeat hexapeptide can bind to the ERC and that VGVAPG is the optimal ligand for high-affinity binding to this cell surface receptor. 18 -20 Therefore, in order to examine whether EP-induced atherosclerosis is specifically dependent on ERC in vivo, we used the VGVAPG synthetic peptide. A dose of 20 mg/kg VGVAPG was used since it has been demonstrated that, compared with kE, a four-fold higher concentration of single peptide is necessary to achieve the equivalent physiological stimulation levels of a bioactive EP released following elastin degradation. 
Haematopoietic PI3Kg is required for EP-induced atherosclerosis
Our team has previously described that PI3Kg is a crucial molecular relay in EP-mediated ERC signalling in fibroblasts. 11 Moreover, we have also provided evidence that loss of PI3Kg function in the haematopoietic lineage is sufficient to prevent atherosclerosis development. 13 Figure 2A and B). These mice were injected with kE (5 mg/kg) or vehicle (PBS) once a week as described for Figure 1 . Analysis of atherosclerotic plaques in aortic roots revealed that EP injections into WT LDLR ) and confirms our results described in Figure 1 ( Figure 3A and B) . Interestingly, injection of EP into PI3Kg 2/2 LDLR 2/2 mice had no effect on lesion size or plasma cholesterol levels compared with control mice ( Figure 3D , E and F). Thus, these results suggest that PI3Kg in the haematopoietic lineage regulates atherosclerosis induced by EP signalling. 
PI3Kg and neuraminidase are involved in EP-induced ROS production and migration of monocytes
The biological functions of EP first described in monocytes was their ability to induce the production of ROS and migration, both of which contribute towards atherogenesis. 22 -24 We, therefore, investigated the possible role of PI3Kg and neuraminidase in these processes. Thus, circulating monocytes isolated from PI3Kg +/+ and PI3Kg
2/2
mice were stimulated in vitro with kE or VGVAPG pre-treated or not with DANA, a specific neuraminidase inhibitor able to block the biological activities of the ERC and elastokine-induced signalling 9, 25 ( Figure 4) . EP-induced ROS production ( Figure 4A and C ) and migration ( Figure 4B and D) were reduced to the same extent by both the absence of PI3Kg or following treatment with DANA. Moreover, treatment with DANA had no additional effects on VGVAPG-induced ROS production and migration in PI3Kg 2/2 monocytes (data not shown), suggesting that PI3Kg and neuraminidase are in the same signalling pathway. These results show that neuraminidase and PI3Kg are key transducers of EP-induced ROS production and migration in monocytes.
EP control PI3Kg activity in a neuraminidase-dependant manner in monocytes
To further delineate the signalling cascades involved in EP stimulation of monocytes, we measured the impact of DANA on PI3Kg activity. We measured PI3Kg activity in p110g immunoprecipitates using an in vitro PI3K activity assay with PI as a substrate and found that kE treatment increased PI3K activity ( Figure 5A ). To confirm these results, we evaluated the phosphorylation of Akt, a well-known effector of PI3K lipid kinase activity. kE treatment increased Akt phosphorylation on threonine 308 without any changes in total Akt expression ( Figure 5B ), indicating that PI3K activity was increased by EP stimulation. Interestingly, pre-treatment with DANA reduced EP-induced activity back to control levels ( Figure 5A and B) , demonstrating that neuraminidase activity is a pre-requisite for EP-induced activation of PI3Kg in monocytes. Elastin peptides potentiate atherosclerosis 3.6 Decreased Neu1 activity in the haematopoietic lineage is sufficient to reduce atherosclerosis in LDLR 2/2 mice During the inflammatory response in the progression of atherosclerosis, elastinolytic enzymes are released which cleave insoluble elastin within the arteries to generate endogenous EP. 26 To better identify the dynamics for EP appearance, we observed elastic lamellae degradation in LDLR 2/2 mice fed an atherogenic diet for 6 or 12 weeks using elastin autofluorescence analysis. 27 No degradation was observed after 6
weeks of atherogenic diet but by 12 weeks elastic lamellae appeared totally degraded, indicating that EP production occurred predominantly after 6 weeks ( Figure 6A) .
To assess the role of Neu1 in atherosclerosis induced by endogenous EP in vivo, we generated a mouse model with catalytically defective Neu1 in haematopoietic cells by BM transplant from CathA/Neu1-deficient mice (CathA S190A-Neo mouse) to irradiated LDLR 2/2 -recipient mice (CathA S190A-Neo LDLR 2/2 ). These CathA S190A-Neo mice presented a 90% reduction in Neu1 activity in leucocytes compared with WT cells. 16, 28 Transplantation efficiency was verified by the detection of
mice, attesting a high percentage of donor BM recovery (see Supplementary material online, Figure 2A and C). Plasma lipid analysis of CathA S190A-Neo LDLR 2/2 mice fed an atherogenic diet for 12 weeks showed no modification compared with LDLR 2/2 mice transplanted with WT BM (WT LDLR 2/2 ) ( Figure 6B ). In contrast analysis of lipid deposition in aortic roots section showed dramatic decrease in the lesion size in CathA S190A-Neo LDLR 2/2 mice compared control mice ( Figure 6C) . Moreover, cellular composition of atherosclerotic lesion showed an important reduction of monocytes and lymphocytes infiltration in the absence of CathA-Neu1 complex ( Figure 6D and E) . Altogether, these data indicate that haematopoietic Neu1 expression is indispensable in the formation of atherosclerotic lesions in mice.
Discussion
EP are one of the major products of ECM degradation that occurs during inflamm-aging, and now a growing body of evidence suggests that they can also affect adjacent/circulating cells and contribute to the progression of age-associated chronic inflammatory diseases such as atherosclerosis. 1, 29 Despite this, an active function for EP in the induction of atheroma plaque progression is yet to be clearly demonstrated. Here, we provide clear evidence that circulating EP are enhancers of atherosclerosis development in two different mouse models of atherosclerosis. Serum concentrations of EP fluctuate from the ng/mL to the mg/ mL range depending on the procedure used for EP dosage and the type of atherosclerotic disease of the patients. 2,4,30 Thus, we injected mice with a dose of EP corresponding to the elevated doses found in the circulating blood of the human 'atherosclerotic' population, 2 taking into consideration that 50% of the injected EP was measured in the urine of mice 1 h after injection and that 1 day after injection ,10% was detected in the blood. 31 Indeed, it has been described that a circulating dose of 0.5 mg/kg EP can be detected in the blood of general atherosclerotic human population. 2 Therefore, the injection of 5 mg/kg kE leads in 24 h to the same concentration found in humans. The inductive effect on atherosclerosis development was also observed after injection of a synthetic peptide VGVAPG which is known to bind with high avidity to EBP 19 and transduce signalling path- 36 This kinase is especially indispensable in leucocyte migration in response to chemokines and in the oxidative burst of monocytes in response to fMLP (formyl-methionyl-leucyl-phenylalanine). 14, 37 Since in vitro studies have demonstrated that EP exert a powerful chemotactic effect on monocytes and stimulate their free-radical production 23, 38 we investigated the possibility that PI3Kg relays signals in both of these biological functions during atherogenesis. Our in vitro experiments performed in WT-and PI3Kg-deficient monocytes provide evidence that neuraminidase activity is essential for PI3Kg-mediated induction of both functions, but the mechanism by which PI3Kg is activated remains to be elucidated. One hypothesis is that Neu1-dependent lactosylceramide production described as a central messenger in ERC signalling 10 is linked to the heterotrimeric Gi proteins that are involved in PI3Kg activation and are known as targets of the ERC. 1 This glycosphingolipid is reported to directly regulate Lyn activation through interaction via its acyl chains. It is thought that the hydrophobic chains of lactosylceramide protrude into the cytoplasmic membrane leaflet and direct van der Waals interactions between itself and the acyl chains of Lyn leading to a conformational modification and activation of Lyn. 39 It is conceivable that the same mechanism applies in the regulation of other acyl chain-anchored proteins such as Gi proteins or other signal tranducers, as has been previously suggested. 40 In addition to their pro-inflammatory effects on monocytes, it has been shown that EPs are able in vitro to polarize T cells that express EBP on their surface, shifting them towards the Th1 response. 41 Regarding the importance of this subpopulation of T cells in atherogenesis, 42 we investigated the possible effect of EP in Th1 response in vivo. Analysis of the expression of T-bet and TIM-3 expression, both transcription factor specifically activated in Th1 cells, did not show any modification in EP-treated LDLR 2/2 mice compared with LDLR 2/2 mice, suggesting that EP were not involved in adaptive immunity during atherogenesis (data not shown). However, it is worth noting that injection of EP represents an artificial model and that the pulse/loading-dose effect of external administration may trigger mechanisms not involved in spontaneous disease. These points bring out the limit of such approach necessitating validation of these data using an endogenous model of EP production. During the inflammatory response, the release of elastases by leucocytes infiltrating the arterial wall at the site of injury contributes to an increase in the cleavage of insoluble elastin, generating endogenous EP and thus leading to the development of atherosclerosis. We observed a clear degradation of the integrity of elastic lamellae in the arteries of LDLR 2/2 mice fed an atherogenic diet, suggesting that during atheroma size progression there is a local production of EP in the arterial wall. Previous work conducted in vitro showed that the removal of b-Gal or PP/ CathA hinders the formation of active Neu1 43 and that Neu1 is an indispensable component of a functional ERC to relay the EP signalling response. 9 To evaluate the effect of endogenous EP on atherosclerosis development, we used a mouse model devoid of CathA/Neu1 catalytic activity in immune cells. Our results demonstrate that a functional immune ERC is indispensable for driving atherosclerosis development, suggesting that Neu1 is essential for mediating the response of endogenous EP in this context. Moreover, decreased infiltrated leucocytes in the absence of Neu1 in haematopoietic lineage suggest that endogenous EP is involved in chemotactism of immune cells reinforcing our in vitro data. Nevertheless, it is important to note that the CathA-Neu1 complex is also involved in lysosomal function and other plasma membrane biological processes outside the ERC. 44 Indeed, the ERC derives from a lysosomal degradation complex of b-gal-CathA-Neu1. The generation of a CathA S190A-Neo mouse leads to the absence of CathA expression and a drastic reduction in Neu1 activity 16 which affects EP signalling since Neu1 transduces its signal, but other biological processes are also affected. In summary, this work has identified EP as an enhancer of atherogenesis and defines Neu1-PI3Kg as key mediators of this function, driving the monocyte response to EP. Taken together, our data further illustrate the critical importance of controlling the production of endogenous EP and their signalling downstream of the ERC in the progression of arterial disease.
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